MDUFA VI Negotiations Turn To RWE Strategy, Presubmission Reforms

 
• By Elizabeth Orr
  
The FDA recently released minutes from a Jan. 21 MDUFA meeting, at which real-world evidence and de novo concerns were on the agenda. (Faizal Ramli/Shutterstock)

More from US FDA

More from Medtech Insight